Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment

ADPKD is characterized by progressive cyst formation and enlargement leading to renal failure. Tolvaptan is currently the only FDA-approved treatment for ADPKD; however, it can cause serious adverse effects including hepatotoxicity. There remains an unmet clinical need for effective and safe treatments for ADPKD. The extracellular Ca2+-sensing receptor (CaSR) is a regulator of epithelial ion transport. FDA-approved CaSR activator cinacalcet can reduce cAMP-induced Cl − and fluid secretion in various epithelial cells by activating phosphodiesterases (PDE) that hydrolyze cAMP.

Source: Translational Research - October 28, 2023 Category: Research Authors: Pattareeya Yottasan, Tifany Chu, Parth D. Chhetri, Onur Cil Source Type: research